Biomaterial Database

[Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)]. 1974

E Schneider, and P A Fischer, and P Jacobi

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010300	Parkinson Disease	A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011292	Premedication	Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION.	Premedications
D002262	Carboxy-Lyases	Enzymes that catalyze the addition of a carboxyl group to a compound (carboxylases) or the removal of a carboxyl group from a compound (decarboxylases). EC 4.1.1.	Carboxy-Lyase,Decarboxylase,Decarboxylases,Carboxy Lyase,Carboxy Lyases
D004295	Dihydroxyphenylalanine	A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.	Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D004359	Drug Therapy, Combination	Therapy with two or more separate preparations given for a combined effect.	Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly

Related Publications

E Schneider, and P A Fischer, and P Jacobi

[Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].

May 1976, MMW, Munchener medizinische Wochenschrift,

E Schneider, and P A Fischer, and P Jacobi

[Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].

December 1976, Ceskoslovenska psychiatrie,

E Schneider, and P A Fischer, and P Jacobi

Treatment of Parkinson's disease with amantadine and L-Dopa.

January 1972, European neurology,

E Schneider, and P A Fischer, and P Jacobi

L-dopa and amantadine hydrochloride in Parkinson's disease.

April 1971, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology,

E Schneider, and P A Fischer, and P Jacobi

The treatment with L-dopa and amantadine in Parkinson's disease.

January 1975, Therapia Hungarica (English edition),

E Schneider, and P A Fischer, and P Jacobi

[Treatment of Parkinson's syndrome with L-dopa associated with diphenhydramine hydrochloride and amantadine hydrochloride].

January 1970, Sistema nervoso,

E Schneider, and P A Fischer, and P Jacobi

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.

September 2000, Movement disorders : official journal of the Movement Disorder Society,

E Schneider, and P A Fischer, and P Jacobi

[Sleep in patients with Parkinson's disease and its influence by L-DOPA (author's transl)].

June 1974, Journal of neurology,